Sana Biotechnology (SANA) EVP and CFO Brian Piper files initial Form 3

Rhea-AI Filing Summary

Sana Biotechnology EVP and CFO Brian Piper filed an initial Form 3 insider report. This filing establishes his status as a reporting insider of Sana Biotechnology, Inc. It does not list any buy or sell transactions and serves as a baseline disclosure of his beneficial ownership reporting obligations.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Piper Brian

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/17/2026

3. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Aaron M. Grossman, Attorney-in-Fact for Brian Piper	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Sana Biotechnology (SANA) Form 3 filing by Brian Piper mean?

The Form 3 filing shows that Brian Piper, EVP and Chief Financial Officer, is now a reporting insider of Sana Biotechnology, Inc. It is an initial ownership statement and does not report any stock purchase or sale transactions.

Did Sana Biotechnology (SANA) EVP CFO Brian Piper buy or sell shares in this Form 3?

No transactions are reported in this Form 3 for Brian Piper. The filing contains no buy, sell, acquire, or dispose entries, indicating it functions solely as an initial insider ownership registration rather than documenting trading activity.

Who is the insider named in the Sana Biotechnology (SANA) Form 3?

The insider is Brian Piper, who serves as Executive Vice President and Chief Financial Officer of Sana Biotechnology, Inc. The Form 3 formally identifies him as a reporting person subject to insider ownership disclosure requirements under U.S. securities rules.

Is the Sana Biotechnology (SANA) Form 3 for Brian Piper a routine filing?

Yes, this Form 3 appears to be routine. It is an initial statement of beneficial ownership for executive Brian Piper and does not describe any significant corporate events, financial changes, or material insider trading transactions for Sana Biotechnology, Inc.

Does the Sana Biotechnology (SANA) Form 3 affect existing shareholders?

The Form 3 itself does not directly change shareholder positions. It simply records Brian Piper as a reporting insider without new transactions, so it provides transparency on insider status but does not alter share counts or company capital structure.